Kerrisdale Capital: Proteostasis Therapeutics Inc (PTI) – Don’t Hold Your Breath

We are short shares of Proteostasis Therapeutics, a clinical-stage biopharmaceutical company whose lead drug, PTI-428, aims to treat the genetic disorder cystic fibrosis. Proteostasis claims that the drug works in a unique way, by somehow increasing the levels of messenger RNA and protein corresponding to the so-called CFTR gene that is dysfunctionally mutated in people with the disease and that gives rise to its ultimately fatal symptoms.

Get The Timeless Reading eBook in PDF

Get...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Proteostasis Therapeutics [+]    PTI [+]    Proteostasis [+]    RNA [+]    CFTR [+]    Timeless Reading [+]    PDF [+]   

More #news: